Anti Myositis Drugs and Market research

Anti Myositis Drugs and Market research Submit Abstract Register Now

The key factors responsible for the dominance in myositis market can be the presence of high geriatric population along with high demand for advanced therapeutics for effective treatment of the disorder in many regions. In some cases there is no complete cure for myositis so researchers are working to develop universal treatment that can be more effective. Studies are also being conducted to find new drugs and therapeutics. 

The global market revenue for advanced orthopaedics grew from $35.3 billion in 2013 to $36.4 billion in 2014. The global orthopaedic device market was valued at $29.2 billion in 2012 and is expected to reach $41.2 billion by 2019. The market is expected to grow at a compound annual growth rate of 4.9 % over the next five years, according to the Transparency Market Research report. The global rheumatology therapeutics market was estimated to be worth $17.1 billion in 2011, having grown at a Compound Annual Growth Rate (CAGR) of 9.4% from 2005, and is forecast to grow at a CAGR of 4.8% to $23.8 billion by 2018. Companies that produce myositis drugs: Gradalis, Inc., New Zealand Pharmaceuticals Ltd., Nobelpharma Co. Ltd., Novartis AG.,  Drugs u Bayer Healthcare, Bloomberg Medical Group, Bone SA, BSN Medical (PTY) Ltd South Africa, DJO Global, Elite Surgical, FLUOROVIZION, KARL STORZ Endoscopy (South Africa) (PTY) LTD, MEDISMEDICAL, Ortho-Xact, Professional Orthopaedics (PTY) LTD, SportsMed Ortho (Pty) Ltd,  Smith & Nephew, STRATMED, SURGITECH,  WERKOMED.

  • Drugs and myositis treatment
  • Case Studies
  • Companies that produce myositis drugs
  • Strategies to contain outbreaks on local and global scenarios
  • Clinical trials in myositis
  • Diagnostic machines and equipments
  • The global market revenue for advanced myositis treatment

Anti Myositis Drugs and Market research Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in